Active surveillance of adverse events of special interest (AESI)
Part II of the study will provide information of adverse events related to COVID-19
vaccinations to the Drug Office of Hong Kong by performing weekly surveillance of the data.
The study aims to allow efficient analysis of adverse events following COVID-19 vaccination, upon linking the adverse event to the vaccine, the information can be used to set up an early warning system of potential adverse events.
This study involves the identification of adverse events following COVID-19 vaccination, cases will be reviewed by an expert group consisting of a medical specialist, a pharmacist and an epidemiologist. The reviewed results will be reported to the Drug Office for further regulatory actions.
Active surveillance of adverse event of special interest (AESI)